JP2010031006A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010031006A5 JP2010031006A5 JP2009165467A JP2009165467A JP2010031006A5 JP 2010031006 A5 JP2010031006 A5 JP 2010031006A5 JP 2009165467 A JP2009165467 A JP 2009165467A JP 2009165467 A JP2009165467 A JP 2009165467A JP 2010031006 A5 JP2010031006 A5 JP 2010031006A5
- Authority
- JP
- Japan
- Prior art keywords
- type
- group
- salt
- diabetes
- therapeutic agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000003839 salts Chemical class 0.000 claims 13
- 239000003814 drug Substances 0.000 claims 10
- 229940124597 therapeutic agent Drugs 0.000 claims 9
- 239000004480 active ingredient Substances 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 7
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 6
- 239000002333 angiotensin II receptor antagonist Substances 0.000 claims 6
- -1 celonapril Chemical compound 0.000 claims 6
- 239000003795 chemical substances by application Substances 0.000 claims 6
- 239000002461 renin inhibitor Substances 0.000 claims 6
- 229940086526 renin-inhibitors Drugs 0.000 claims 6
- 208000032781 Diabetic cardiomyopathy Diseases 0.000 claims 5
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 claims 4
- 239000002876 beta blocker Substances 0.000 claims 4
- 229940097320 beta blocking agent Drugs 0.000 claims 4
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 claims 4
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 claims 4
- 206010012601 diabetes mellitus Diseases 0.000 claims 3
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 3
- BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 claims 2
- MVDXXGIBARMXSA-PYUWXLGESA-N 5-[[(2r)-2-benzyl-3,4-dihydro-2h-chromen-6-yl]methyl]-1,3-thiazolidine-2,4-dione Chemical compound S1C(=O)NC(=O)C1CC1=CC=C(O[C@@H](CC=2C=CC=CC=2)CC2)C2=C1 MVDXXGIBARMXSA-PYUWXLGESA-N 0.000 claims 2
- 239000005541 ACE inhibitor Substances 0.000 claims 2
- UXOWGYHJODZGMF-QORCZRPOSA-N Aliskiren Chemical group COCCCOC1=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=CC=C1OC UXOWGYHJODZGMF-QORCZRPOSA-N 0.000 claims 2
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 claims 2
- 239000002083 C09CA01 - Losartan Substances 0.000 claims 2
- 239000002080 C09CA02 - Eprosartan Substances 0.000 claims 2
- 239000004072 C09CA03 - Valsartan Substances 0.000 claims 2
- 239000002947 C09CA04 - Irbesartan Substances 0.000 claims 2
- 239000002053 C09CA06 - Candesartan Substances 0.000 claims 2
- 239000005537 C09CA07 - Telmisartan Substances 0.000 claims 2
- 108010061435 Enalapril Proteins 0.000 claims 2
- 108010007859 Lisinopril Proteins 0.000 claims 2
- 239000005478 Saprisartan Substances 0.000 claims 2
- DUEWVPTZCSAMNB-UHFFFAOYSA-N Saprisartan Chemical compound NC(=O)C=1N(CC=2C=C3C(Br)=C(OC3=CC=2)C=2C(=CC=CC=2)NS(=O)(=O)C(F)(F)F)C(CC)=NC=1C1CC1 DUEWVPTZCSAMNB-UHFFFAOYSA-N 0.000 claims 2
- 229960004601 aliskiren Drugs 0.000 claims 2
- 229940126317 angiotensin II receptor antagonist Drugs 0.000 claims 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 2
- 229960004530 benazepril Drugs 0.000 claims 2
- MADRIHWFJGRSBP-ROUUACIJSA-N benazeprilat Chemical compound C([C@H](N[C@H]1CCC2=CC=CC=C2N(C1=O)CC(=O)O)C(O)=O)CC1=CC=CC=C1 MADRIHWFJGRSBP-ROUUACIJSA-N 0.000 claims 2
- 229960000932 candesartan Drugs 0.000 claims 2
- SGZAIDDFHDDFJU-UHFFFAOYSA-N candesartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SGZAIDDFHDDFJU-UHFFFAOYSA-N 0.000 claims 2
- 229960000830 captopril Drugs 0.000 claims 2
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 claims 2
- YZFWTZACSRHJQD-UHFFFAOYSA-N ciglitazone Chemical compound C=1C=C(CC2C(NC(=O)S2)=O)C=CC=1OCC1(C)CCCCC1 YZFWTZACSRHJQD-UHFFFAOYSA-N 0.000 claims 2
- 229950009226 ciglitazone Drugs 0.000 claims 2
- 229960005025 cilazapril Drugs 0.000 claims 2
- HHHKFGXWKKUNCY-FHWLQOOXSA-N cilazapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N2[C@@H](CCCN2CCC1)C(O)=O)=O)CC1=CC=CC=C1 HHHKFGXWKKUNCY-FHWLQOOXSA-N 0.000 claims 2
- QQKNSPHAFATFNQ-UHFFFAOYSA-N darglitazone Chemical compound CC=1OC(C=2C=CC=CC=2)=NC=1CCC(=O)C(C=C1)=CC=C1CC1SC(=O)NC1=O QQKNSPHAFATFNQ-UHFFFAOYSA-N 0.000 claims 2
- 229950006689 darglitazone Drugs 0.000 claims 2
- 229960005227 delapril Drugs 0.000 claims 2
- WOUOLAUOZXOLJQ-MBSDFSHPSA-N delapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N(CC(O)=O)C1CC2=CC=CC=C2C1)CC1=CC=CC=C1 WOUOLAUOZXOLJQ-MBSDFSHPSA-N 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 229960000873 enalapril Drugs 0.000 claims 2
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 claims 2
- 229950002375 englitazone Drugs 0.000 claims 2
- 229960004563 eprosartan Drugs 0.000 claims 2
- OROAFUQRIXKEMV-LDADJPATSA-N eprosartan Chemical compound C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 OROAFUQRIXKEMV-LDADJPATSA-N 0.000 claims 2
- 229960002490 fosinopril Drugs 0.000 claims 2
- 229960001195 imidapril Drugs 0.000 claims 2
- KLZWOWYOHUKJIG-BPUTZDHNSA-N imidapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1C(N(C)C[C@H]1C(O)=O)=O)CC1=CC=CC=C1 KLZWOWYOHUKJIG-BPUTZDHNSA-N 0.000 claims 2
- 229940125396 insulin Drugs 0.000 claims 2
- 229960002198 irbesartan Drugs 0.000 claims 2
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 claims 2
- 229960002394 lisinopril Drugs 0.000 claims 2
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 claims 2
- 229960004773 losartan Drugs 0.000 claims 2
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 claims 2
- PKWDZWYVIHVNKS-UHFFFAOYSA-N netoglitazone Chemical compound FC1=CC=CC=C1COC1=CC=C(C=C(CC2C(NC(=O)S2)=O)C=C2)C2=C1 PKWDZWYVIHVNKS-UHFFFAOYSA-N 0.000 claims 2
- 229960002582 perindopril Drugs 0.000 claims 2
- IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 claims 2
- 229960005095 pioglitazone Drugs 0.000 claims 2
- 229960001455 quinapril Drugs 0.000 claims 2
- JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 claims 2
- 229960003401 ramipril Drugs 0.000 claims 2
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 claims 2
- 229960004586 rosiglitazone Drugs 0.000 claims 2
- 229950006241 saprisartan Drugs 0.000 claims 2
- 229960002909 spirapril Drugs 0.000 claims 2
- 108700035424 spirapril Proteins 0.000 claims 2
- HRWCVUIFMSZDJS-SZMVWBNQSA-N spirapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2(C1)SCCS2)C(O)=O)CC1=CC=CC=C1 HRWCVUIFMSZDJS-SZMVWBNQSA-N 0.000 claims 2
- 229960005187 telmisartan Drugs 0.000 claims 2
- 229960001641 troglitazone Drugs 0.000 claims 2
- 229960004699 valsartan Drugs 0.000 claims 2
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 claims 2
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 230000003796 beauty Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 claims 1
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 claims 1
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8146908P | 2008-07-17 | 2008-07-17 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010031006A JP2010031006A (ja) | 2010-02-12 |
| JP2010031006A5 true JP2010031006A5 (enExample) | 2012-08-02 |
Family
ID=41735939
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009165467A Pending JP2010031006A (ja) | 2008-07-17 | 2009-07-14 | 有機化合物の使用 |
Country Status (2)
| Country | Link |
|---|---|
| US (1) | US20100093603A1 (enExample) |
| JP (1) | JP2010031006A (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116115763A (zh) * | 2021-11-12 | 2023-05-16 | 成都贝诺科成生物科技有限公司 | 一种含有h1组胺受体拮抗剂的联合用药物 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5834466A (en) * | 1994-12-22 | 1998-11-10 | The Regents Of The University Of California | Method for protecting of heart by limiting metabolic and ionic abnormalities developed during ischemia, following ischemia or resulting from ischemia |
| US7048914B2 (en) * | 2002-12-12 | 2006-05-23 | Zoltan Laboratories | Placental alkaline phosphatase to control diabetes |
| AR048431A1 (es) * | 2004-03-17 | 2006-04-26 | Novartis Ag | Formulaciones galenicas de compuestos organicos |
| MY146830A (en) * | 2005-02-11 | 2012-09-28 | Novartis Ag | Combination of organic compounds |
| CA2626682A1 (en) * | 2005-11-08 | 2007-05-18 | Novartis Ag | Combination of an angiotensin ii receptor blocker, a calcium channel blocker and another active agent |
| GB0612540D0 (en) * | 2006-06-23 | 2006-08-02 | Novartis Ag | Galenical formulations of organic compounds |
-
2009
- 2009-07-14 US US12/502,418 patent/US20100093603A1/en not_active Abandoned
- 2009-07-14 JP JP2009165467A patent/JP2010031006A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018507244A5 (enExample) | ||
| HRP20110969T4 (hr) | Pimobendan za upotrebu za smanjenje veličine srca kod sisavaca koji pate od srčane insuficijencije | |
| WO2001076573A2 (en) | Combination of at least two compounds selected from an at1-receptor antagonist or an ace inhibitor or a hmg-co-a reductase inhibitor groups | |
| JP6224597B2 (ja) | グリオーマを処置するための組成物及び方法 | |
| WO2010075347A2 (en) | Methods of treating hypertension with at least one angiotensin ii receptor blocker and chlorthalidone | |
| CN1230122A (zh) | 药物组合物 | |
| RU99103215A (ru) | Фармацевтическая композиция | |
| RU2015110979A (ru) | Комбинации ингибиторов sglt 2 и антигипертензивных лекарственных средств | |
| SK2062003A3 (en) | Pharmaceutical combination of angiotensin II antagonists and ACE inhibitors | |
| AU766453C (en) | Use of angiotensin II receptor antagonists for treating acute myocardial infarction | |
| CN1187050C (zh) | 内皮素拮抗剂和血管紧张肽原酶－血管紧张肽系统抑制剂的联合体系 | |
| EP1799199B1 (en) | Use of renin inhibitors for the prevention or treatment of diastolic dysfunction or diastolic heart failure | |
| Morganti et al. | Aliskiren: the first direct renin inhibitor available for clinical use | |
| US6544968B2 (en) | Use of angiotensin II receptor antagonists for treating acute myocardial infarction | |
| Van Zwieten | Angiotensin II receptor antagonists (AT1-blockers, ARBs, sartans): similarities and differences | |
| RU2539382C2 (ru) | Лекарственное средство для лечения гипертензии или повышенного кровяного давления | |
| NZ603414A (en) | Association of xanthine oxidase inhibitors and angiotensin ii receptor antagonists and use thereof | |
| WO2009088006A1 (ja) | 併用医薬 | |
| CN100558359C (zh) | 肾小球病治疗剂 | |
| HRP20170267T1 (hr) | Kombinacija (3s,3s') 4,4'-disulfandiilbis(3-aminobutan 1-sulfonske kiseline) i drugog antihipertenzivnog agensa | |
| HRP20030124A2 (en) | Pharmaceutical combination of angiotensin ii antagonists and angiotensin i converting enzyme inhibitors | |
| ES2332884T3 (es) | Tratamiento de la lipodistrofia con inhibidores del sistema renina angiotensina. | |
| NZ531346A (en) | Medicinal compositions containing angiotensin II receptor antagonist | |
| WO2005053687A1 (en) | Combination of organic compounds | |
| JP2010518147A (ja) | 有機化合物の使用 |